From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

TAIPEI, Taiwan, October 16, 2026--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets.

Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabilities spanning in-house discovery and research, clinical development, manufacturing, global supply and commercialization, according to the company.

This infrastructure enables the company to bring its own innovations from the laboratory to international markets and supply medicines to patients worldwide, PharmaEssentia said.

The company continues expanding its global reach after securing U.S. and Japanese approvals in August for ropeginterferon alfa-2b (Ropeg) to treat essential thrombocythemia (ET), a rare blood cancer that causes excessive platelet production. These approvals followed Taiwan's approval in May for adult ET patients resistant to or intolerant of hydroxyurea (HU).

According to PharmaEssentia, Ropeg, marketed under the brand name BESREMi, is the first new treatment approved for ET in nearly three decades and the only drug approved by the U.S. FDA for both ET and polycythemia vera (PV), another rare blood cancer.

The company said the approvals marked a major milestone in its efforts to expand the drug's applications and benefit more patients worldwide.

Ropeg, a long-acting interferon-based medication invented by PharmaEssentia founder and CEO, Dr. Ko-Chung Lin, was first approved for PV treatment in the European Union in 2019, followed by the United States in 2021, and Japan in 2023. The drug has since been approved and launched for PV treatment in approximately 50 countries, according to the company.

Lin invented Ropeg using proprietary PEGylation technology and advanced small-molecule synthesis techniques to link polyethylene glycol (PEG) to interferon alfa, producing a long-acting interferon with a stable chemical structure and uniform composition, according to PharmaEssentia.

PharmaEssentia said it retains full global intellectual property rights across all indications.

Ropeg reflects PharmaEssentia's integrated capabilities across the drug development value chain, according to the company.

PharmaEssentia manufactures Ropeg itself to supply patients worldwide and holds the key technologies and patents for its development, manufacturing and use, it said.